Meet with... New Enterprise Associates

Jun 29 2016

New Enterprise Associates, Inc. (NEA) has a strong track record of investing in innovative companies that are transforming the healthcare industry. NEA has nearly $17 billion in committed capital and is currently investing $2.8 billion from their 15th Fund (NEA 15). Can you be their next investment?

Apply today for an opportunity to meet with a representative from NEA.

Program Overview:
NEA, a global venture capital firm focused on helping entrepreneurs building transformational businesses across multiple sectors and stages, is visiting Johnson & Johnson Innovation, JLABS (JLABS) on June 29, 2016. NEA invests in life science innovators with biopharma focus areas including clinical drug development and drug discovery.

Since 1977, NEA has partnered with technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions.

Carol Gallagher, Pharm.D., Partner at NEA, will be in attendance to give an overview presentation covering key areas of interest and best practices when seeking startup funds. Following the presentation, don't miss this opportunity to introduce yourself to Carol during the networking lunch.

For those companies who apply online and are approved, one-on-one meetings with NEA will provide a brief forum to discuss your company. NEA's healthcare investing has a focus biopharmaceuticals, healthcare services/IT and medical devices. Leaders from the life science industry are encouraged to apply today to meet with NEA!

10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on May 25th.

About NEA:
New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in committed capital, NEA invests in information technology, healthcare and energy technology companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions. For additional information,

NEA Participating Representative:
Carol Gallagher, Pharm.D. | Partner, New Enterprise Associates, Inc.
Carol Gallagher joined New Enterprise Associates (NEA) in October 2014, where she is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with more than 25 years of experience in commercial, drug development and business development roles. Prior to joining NEA, she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards including Aragon Pharmaceuticals, which was acquired in 2013 by Johnson and Johnson for $650 million upfront and a total consideration of $1 billion. From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. During her tenure as CEO at Calistoga Pharmaceuticals, Dr. Gallagher raised $80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for $375 million and a total consideration of $600 million. Gilead has continued to rapidly advance registration trials of ZYDELIG in patients with certain types of leukemia and lymphoma. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously.
Connect with Carol: Connect on LinkedIn

$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 28th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on May 25th. Your application will be reviewed and you will be notified of acceptance on June 15th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

3210 Merryfield Row
San Diego, CA